PET scan contribution in chest tumor management: A systematic review for thoracic surgeons

Tumori

Volumn 98, Issue 2, 2012, Pages 175-184

  Duranti, Leonardo ^a   Leo, Francesco ^a   Pastorino, Ugo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Lung cancer; PET scan; Thoracic tumors

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GA(III) DOTATOC; GA(III)-DOTATOC; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; FALSE NEGATIVE RESULT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDIASTINUM TUMOR; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURGEON; SYSTEMATIC REVIEW; THORAX TUMOR; THORAX WALL TUMOR; THYMOMA; TREATMENT PLANNING; EARLY DIAGNOSIS; ESOPHAGUS TUMOR; LUNG NODULE; LUNG TUMOR; MESOTHELIOMA; METABOLISM; METHODOLOGY; PLEURA TUMOR; PREDICTIVE VALUE; PROGNOSIS; SCINTISCANNING;

EARLY DETECTION OF CANCER; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MEDIASTINAL NEOPLASMS; MESOTHELIOMA; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; SOLITARY PULMONARY NODULE; THORACIC NEOPLASMS; THYMOMA; THYMUS NEOPLASMS;

EID: 84864882093     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800201     Document Type: Review

References (99)

1. Schlyer DJ: PET tracers and radiochemistry. Ann Acad Med Singapore, 33: 146-154, 2004.
2. Cellerino A, Filippi PG, Chiantaretto A, Borasio P: Operative and pathologic survey of 50 cases of peripheral lung tumors scanned with 67 gallium. Chest, 64: 700-705, 1973.
3. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R: A combined PET/CT scanner for clinical oncology. J Nucl Med, 41: 1369-1379, 2000. (Pubitemid 30643379)
4. Schöder H, Erdi YE, Larson SM, Yeung HW: PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging, 30: 1419-1437, 2003. (Pubitemid 37247962)
5. Wieseler B, McGauran N: Reporting a Systematic Review. Chest, 137: 1240-1246, 2010.
6. Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, Pelosi G, Boyle P, Fazio F: Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet, 362: 593-597, 2003. (Pubitemid 37013298)
7. Wahidi MM, Govert JA, Goudar RK: Evidence for treatment of patients with pulmonary nodules: when is it lung cancer? An ACCP evidence-based clinical practice guideline, 2nd edition. Chest, 132: 94-107, 2007.
8. Croft DR, Trapp J, Kernstine K, Kirchner P, Mullan B, Galvin J, Peterson MW, Gross T, McLennan G, Kern JA : FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung cancer, 36: 297-301, 2002. (Pubitemid 34497130)
9. Yüksel M, Akgül AG, Evman S, Batirel HF: Suture and stapler granulomas: a word of caution. Eur J Cardiothorac Surg, 31: 563-565, 2007. (Pubitemid 46329382)
10. 18fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer, 45: 19-27, 2004.
11. Ohba Y, Nomori H, Shibata H, Kobayashi H, Mori T, Shiraishi S, Nakashima R: Evaluation of semiquantitative assessments of fluorodeoxyglucose uptake on positron emission tomography scans for the diagnosis of pulmonary malignancies 1 to 3 cm in size. Ann Thorac Surg, 87: 886-891, 2009.
12. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK: Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA, 285: 914-924, 2001. (Pubitemid 32171553)
13. Veronesi G, Bellomi M, Veronesi U, Paganelli G, Maisonneuve P, Scanagatta P, Leo F, Pelosi G, Travaini L, Rampinelli C, Trifirò G, Sonzogni A, Spaggiari L: Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. Ann Thorac Surg, 84: 959-966, 2007. (Pubitemid 47285033)
14. 18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nuclear Medicine, 34: 355-359, 1993.
15. Lucignani G, Paganelli G, Bombardieri E: The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun, 25: 651-656, 2004. (Pubitemid 38901681)
16. Boellaard R: Standards for PET image acquisition and quantitative data analysis. J Nucl Med, 50: 11-20, 2009.
17. 18fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. Ann Thorac Surg, 79: 984-988, 2005.
18. 18F-FDG PET in malignant tumors. J Nucl Med, 49: 1804-1808, 2008.
19. Krak NC, Boellaard R, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA: Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging, 32: 294-301, 2005. (Pubitemid 40562120)
20. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med, 43: 871-875, 2002.
21. Arenberg D, American College of Chest Physicians: Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132: 306-313, 2007.
22. Goudarzi B, Jacene HA, Wahl RL: Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. J Nucl Med, 49: 1585-1592, 2008.
23. Sun JS, Park KJ, Sheen SS, Yoon JK, Yoon SN, Lee KB, Hwang SC: Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers. Lung Cancer, 66: 205-210, 2009.
24. Lee HY, Lee KS, Han J, Kim BT, Cho YS, Shim YM, Kim J: Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons. Lung Cancer, 65: 170-175, 2009.
25. 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness. Ann Nucl Med, 23: 609-616, 2009.
26. 18F- fluorodeoxyglucose.Nucl Med Commun, 31: 389-397, 2010.
27. 18F-FDG-PET. Ann Nucl Med, 22: 533-538, 2008.
28. Krüger S, Buck AK, Blumstein NM, Pauls S, Schelzig H, Kropf C, Schumann C, Mottaghy FM, Hombach V, Reske SN: Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med, 260: 545-550, 2006. (Pubitemid 44772374)
29. Daniels CE, Aubry MC, Allen MS, Jett JR: The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest, 131: 255-260, 2007. (Pubitemid 46123001)
30. 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med, 50: 1927-1932, 2009.
31. Chong S, Lee KS, Kim BT, Choi JY, Yi CA, Chung MJ, Oh DK, Lee JY: Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol, 188: 1223-1231, 2007. (Pubitemid 46668502)
32. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA: The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with non small cell lung cancer. Ann Thorac Surg, 78: 1017-1023, 2004. (Pubitemid 39164825)
33. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K: The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. J Thorac Cardiovasc Surg, 127: 1087-1092, 2004. (Pubitemid 38451942)
34. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, Choi JY, Kwon OJ, Shim YM, Kim S: Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology, 236: 1011-1019, 2005. (Pubitemid 41170866)
35. 18FDG-PET. Thorac Cardiovasc Surg, 52: 96-101, 2004.
36. Gupta NC, Graeber GM, Bishop HA: Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest, 117: 773-778, 2000. (Pubitemid 30152219)
37. Roberts PF, Follette DM, von Haag D, Park JA, Valk PE, Pounds TR, Hopkins DM: Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg, 70: 1154-1159, 2000.
38. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, Heelan RT, MacApinlac HA, Jung SH, Silvestri GA, Siegel BA, Rusch VW; American College of Surgeons Oncology Group Z0050 trial: Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg, 126: 1943-1951, 2003. (Pubitemid 38020756)
39. Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH, Corstens FH, Oyen WJ: FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer, 44: 175-181, 2004. (Pubitemid 38482050)
40. 18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with nonsmall cell lung cancer. Eur J Nucl Med, 25: 1244-1247, 1998.
41. Viney RC, Boyer MJ, King MT, Kenny PM, Pollicino CA, McLean JM, McCaughan BC, Fulham MJ: Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol, 22: 2357-2362, 2004. (Pubitemid 41115392)
42. 18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol, 24: 1800-1806, 2006.
43. Subedi N, Scarsbrook A, Darby M, Korde K, Mc Shane P, Muers MF: The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer. Lung Cancer, 64: 301-307, 2009.
44. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, van Velthoven PC, Comans EF, Diepenhorst FW, Verboom P, van Mourik JC, Postmus PE, Boers M, Teule GJ: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet, 359: 1388-1393, 2002.
45. Carretta A, Ciriaco P, Canneto B, Nicoletti R, Del Maschio A, Zannini P: Therapeutic strategy in patients with non-small cell lung cancer associated to satellite pulmonary nodules. Eur J Cardiothorac Surg, 21: 1100-1114, 2002.
46. Beatty JS, Williams HT, Aldridge BA, Hughes MP, Vasudeva VS, Gucwa AL, David GS, Lind DS, Kruse EJ, McLoughlin JM: Incidental PET/CT findings in the cancer patient: how should they be managed? Surgery, 146: 274-281, 2009.
47. 18F-fluorodeoxyglucose uptake on positron emission tomography predicts lymph node metastasis and invasiveness in clinical stage IA non-small cell lung cancer. Interact Cardiovasc Thorac Surg, 9: 79-82, 2009.
48. Gauger J, Patz EF Jr, Coleman RE, Herndon JE 2nd: Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. J Thorac Oncol, 2: 499-505, 2007. (Pubitemid 47171803)
49. Okereke IC, Gangadharan SP, Kent MS, Nicotera SP, Shen C, DeCamp MM: Standard uptake value predicts survival in non-small cell lung cancer. Ann Thorac Surg, 88: 911-916, 2009.
50. Pastorino U, Landoni C, Marchianò A, Calabrò E, Sozzi G, Miceli R, Picchio M, Mariani L, Messa C, Fazio F: Fluorodeoxyglucose uptake measured by positron emission tomography and standardized uptake value predicts long-term survival of CT screening detected lung cancer in heavy smokers. J Thorac Oncol, 4: 1352-1356, 2009.
51. 18F-fluorodeoxyglucose (FDG) uptake and prognosis in patients with resected, clinical stage Ia non-small cell lung cancer. Chest, 137: 1150-1156, 2010.
52. 18fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. J Thorac Cardiovasc Surg, 133: 1419-1427, 2007.
53. 18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected non-small cell lung carcinoma. Lung Cancer, 69: 187-193, 2010.
54. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK: Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol, 9: 1193-1198, 1998. (Pubitemid 28552808)
55. Cerfolio RJ, Bryant AS, Ojha B: Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg, 131: 1229-1235, 2006. (Pubitemid 43792421)
56. 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol, 4: 816-821, 2009.
57. 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 55: 165-171, 2007.
58. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging, 34: 463-471, 2007.
59. Pastorino,U, Buyse M, Friedal G: The International Registry of Lung Metastases: Long term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thoracic Cardiovasc Surg, 113: 37-49, 1997. (Pubitemid 27034340)
60. Pastorino U, Veronesi G, Landoni C, Leon M, Picchio M, Solli PG, Leo F, Spaggiari L, Pelosi G, Bellomi M, Fazio F: Fluorodeoxyglucose positron emission tomography improves preoperative staging of resectable lung metastasis. J Thorac Cardiovasc Surg, 126: 1906-1910, 2003. (Pubitemid 38020750)
61. 18F-fluorodeoxyglucose positron emission tomography in the evaluation of metastatic pulmonary nodules. Eur J Cardiothorac Surg, 34: 1223-1227, 2008.
62. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun, 27: 795-802, 2006.
63. Franzius C, Daldrup-Link HE, Sciuk J, Rummeny EJ, Bielack S, Jürgens H, Schober O: FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol, 12: 479-486, 2001. (Pubitemid 32472101)
64. Veronesi G, Landoni C, Pelosi G, Picchio M, Sonzogni A, Leon ME, Solli PG, Leo F, Spaggiari L, Bellomi M, Fazio F, Pastorino U: Fluoro-deoxyglucose uptake and angiogenesis are independent biological features in lung metastases. Br J Cancer, 86: 1391-1395, 2002. (Pubitemid 34552241)
65. Heffner JE, Klein JS, Hampson C: Diagnostic utility and clinical application of imaging for pleural space infections. Chest, 137: 467-479, 2010.
66. Toaff JS, Metser U, Gottfried M, Gur O, Deeb ME, Lievshitz G, Mercer D, Even-Sapir E: Differentiation between malignant and benign pleural effusion in patients with extrapleural primary malignancies: assessment with positron emission tomography-computed tomography. Invest Radiol, 40: 204-209, 2005. (Pubitemid 40393231)
67. Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, Erginel S: Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol, 4: 1480-1484, 2009.
68. 18F-FDG PET imaging in assessing exudative pleural effusions. Nuclear Med Comm, 27: 971-976, 2006.
69. Orki A, Akin O, Tasci AE, Ciftci H, Urek S, Falay O, Kutlu CA: The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg, 57: 217-221, 2009.
70. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. Eur J Cardiothorac Surg, 34: 1090-1096, 2008.
71. Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, Vaporciyan AA, Walsh GL, Sabloff BS, Broemeling LD, Stevens CW, Pisters KM, Podoloff DA, Macapinlac HA: Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg, 129: 1364-1370, 2005. (Pubitemid 40804856)
72. Flores RM: The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer, 49: 27-32, 2005.
73. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A: Prognostic value of FDG PET Imaging in malignant pleural mesothelioma. J Nuclear Med, 40: 1241-1245, 1999. (Pubitemid 29385629)
74. Flores RM, Akhurst T, Gonen M, Zakowski M, Dycoco J, Larson SM, Rusch VW: Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg, 132: 763-768, 2006. (Pubitemid 44415880)
75. 18-fluorodeoxyglucose position emission tomography-computed tomography in patient surveillance after multimodality therapy of malignant pleural mesothelioma. J Thorac Oncol, 5: 385-388, 2010.
76. 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma. J Med Imaging Radiat Oncol, 53: 160-170, 2009.
77. Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, Incarbone M, Alloisio M, Santoro A: Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F] fluorodeoxyglucose. J Clin Oncol, 24: 4587-4593, 2006. (Pubitemid 46630956)
78. 18)F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax - a phantom study. Phys Med Biol, 53: 4213-4230, 2008.
79. Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA: Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer, 67: 311-317, 2010.
80. 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer, 61: 350-355, 2008.
81. Luzzi L, Campione A, Gorla A, Vassallo G, Bianchi A, Biggi A, Terzi A: Role of fluorine-flurodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of anterior mediastinal masses. Eur J Cardiothorac Surg, 36: 475-479, 2009.
82. Kubota K, Yamada S, Kondo T, Yamada K, Fukuda H, Fujiwara T, Ito M, Ido T: PET imaging of primary mediastinal tumours. Br J Cancer, 73: 882-886, 1996. (Pubitemid 26110157)
83. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med, 47: 1628-1634, 2006.
84. 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol, 23: 4643-4651, 2005.
85. MacManus MP, Seymour JF, Hicks RJ: Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging, 7: 10-18, 2007. (Pubitemid 47559835)
86. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica, 85: 613-618, 2000.
87. 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun, 26: 689-694, 2005.
88. 18F] fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer, 94: 2353-2362, 2002.
89. 18Fluoro-deoxy-D- glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol, 22: 1034-1039, 2004.
90. Beaulieu S, Rubin B, Djang D, Conrad E, Turcotte E, Eary JF: Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. Am J Roentgenol, 182: 971-974, 2004. (Pubitemid 38391660)
91. Petermann D, Allenbach G, Schmidt S, Letovanec I, Christodoulou M, Delaloye AB, Ris HB, Prior JO: Value of positron emission tomography in full-thickness chest wall resections for malignancies. Interact Cardiovasc Thorac Surg, 9: 406-410, 2009.
92. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O: The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer, 107: 2545-2551, 2006. (Pubitemid 44845606)
93. 18)F-FDG PET-CT. Ann Nucl Med, 23: 569-577, 2009.
94. 18 fluorodeoxyglucose positron emission tomography in thymic pathology. Eur J Cardiothorac Surg, 31: 731-736, 2007.
95. Heron DE, Andrade RS, Beriwal S, Smith RP: PET-CT in radiation oncology: the impact on diagnosis, treatment planning, and assessment of treatment response. Am J Clin Oncol, 31: 352-362, 2008.
96. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, Bosch W, Bertrand RJ: Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 59: 78-86, 2004. (Pubitemid 38501510)
97. Lavrenkov K, Partridge M, Cook G, Brada M: Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother Oncol, 77: 1-4, 2005. (Pubitemid 41503381)
98. Ashamalla H, Rafla S, Parikh K, Mokhtar B, Goswami G, Kambam S, Abdel-Dayem H, Guirguis A, Ross P, Evola A: The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys, 63: 1016-1023, 2005. (Pubitemid 41505278)
99. 18-FDG uptake in early stage NSCLC. Thorac Cardiovasc Surg, 57: 413-416, 2009.